Form 4: Akero Therapeutics Executive Catriona Yale Reports Stock Transactions
SEC Form 4 Filing
Catriona Yale, Chief Development Officer of Akero Therapeutics, reports the exercise of stock options and subsequent sale of shares under a pre-arranged trading plan.
Summary
- On September 20, 2024, Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised options to acquire 5,500 shares of common stock at a price of $0.615 per share.
- Simultaneously, Yale sold 5,500 shares of common stock at a weighted-average price of $27.652 per share, with prices ranging from $27.50 to $27.87.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2024.
- Following these transactions, Yale directly owns 75,294 shares of Akero Therapeutics common stock and holds options for 27,959 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine insider trading activity under a pre-arranged plan, with no indication of positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's outlook or performance. It reflects the executive's personal financial decisions within the bounds of a pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| May 28, 2024 | Date of adoption of Rule 10b5-1 trading plan. |
| September 19, 2024 | Date of earliest transaction. |
| September 20, 2024 | Date of stock option exercise and sale. |
| September 23, 2024 | Date of signature on the Form 4 filing. |
| October 17, 2028 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.